Bioage Labs (BIOA) Stock Price, Quote, News & History | Benzinga

SPY769.86+0.03%QQQ749.55−0.00%BTC/USD84,637.01+0.16%DIA511.70+0.12%GLD380.52+0.10%TLT77.53+0.06%

Bioage Labs Inc (BIOA) Stock Price, Quote, News & History

BIOANASDAQ

Trade with Public

Trade with Public

$6.61

-0.20-2.94%

Last update: Oct 2, 6:02 PM

$6.74

-0.07-1.03%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$6.92

Close

$6.61

Volume / Avg.

869.99K / 852.23K

Day Range

$6.47 - $6.92

52 Wk Range

5.04 - 25.96

Market Cap

$309.35M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

26

Short Interest

7.53%

Days to Cover

6.06

Recent BioAge Labs, Inc. News

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.

Vandana Singh

Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings

US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon shares jump 14% after posting strong Q2 results.

Avi Kapoor

This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check out what analysts think of GE stock.

Avi Kapoor

This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday

Wall Street analysts changed outlook on top stocks. Check our analyst ratings page for all changes. See opinions on CSHR, BIOA.

Avi Kapoor

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

BioAge Labs says BGE-102 Phase 1 data show strong hsCRP reductions at 60 mg and 120 mg; analysts maintain Buy ratings with higher targets.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-87.60M

Investing Cash Flow (TTM)

-212.85M

Financing Cash Flow (TTM)

154.15M

Free Cash Flow (TTM)

-88.09M

Capital Expenditure (TTM)

-488.00K

Net Change in Cash (TTM)

-146.31M

Analyst Trends and Forecast

2

May

1

Jul

2

Aug

2

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$3.81M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

26.16

PB Ratio (TTM)

0.83

Earnings Yield % (TTM)

-35.15%

Earnings Yield % (FWD)

-35.44%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.17

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$5.66M

Total Cash

$73.96M

Debt to Equity

0.01

Issuance of Debt (TTM)

-$5.66M

Repayment of Debt (TTM)

-$5.66M